Literature DB >> 7071823

Diagnosis of carcinoma of the pancreas by assay of immunosuppressive acidic protein.

S Matsuno, M Kobari, Y Matsuda, T Sato.   

Abstract

To establish a procedure for screening of pancreatic cancer, we assayed the serum level of immunosuppressive acidic protein (IAP) in patients with malignant and benign pancreatic diseases and compared it with the serum level of carcinoembryonic antigen (CEA). In 96% of 46 pancreatic cancer patients, the serum IAP level averaged 928 micrograms/ml; while 500 micrograms/ml or below was obtained as the normal value in 211 healthy adults. The serum IAP level may be elevated in the presence of non-malignant, inflammatory pancreatic diseases. For the differential diagnosis of pancreatic cancer, therefore, other laboratory data need to be taken into account. The serum IAP level was correlated with the progression of pancreatic cancer and may provide a means to determine whether tumor resection was radical or admitting of recurrence. The serum IAP level in samples obtained from different sites of the portal system did not reflect tumor location in patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7071823     DOI: 10.1620/tjem.136.1

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

1.  Effect of alpha 1-acidic glycoprotein in the ascitic fluid of cancer patients on human NK cells: selective suppression of interferon-induced NK activation.

Authors:  H Aso; K Tamura; M T Rose; Y Tomioka; M Mizugaki; N Ishida
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

2.  [Immunosuppressive acid protein in pregnant females and in patients with ovarian cancer].

Authors:  H Kölbl; G Tatra; C Bieglmayer
Journal:  Klin Wochenschr       Date:  1987-12-01

3.  Antitumor effect of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in mice.

Authors:  T Ebina; K Murata; K Tamura
Journal:  Jpn J Cancer Res       Date:  1994-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.